Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report

被引：110

作者：

Owada-Ozaki, Yuki ^{[1
]}

Muto, Satoshi ^{[1
]}

Takagi, Hironori ^{[1
]}

Inoue, Takuya ^{[1
]}

Watanabe, Yuzuru ^{[1
]}

Fukuhara, Mitsuro ^{[1
]}

Yamaura, Takumi ^{[1
]}

Okabe, Naoyuki ^{[1
]}

Matsumura, Yuki ^{[1
]}

Hasegawa, Takeo ^{[1
]}

Ohsugi, Jun ^{[1
]}

Hoshino, Mika ^{[1
]}

Shio, Yutaka ^{[1
]}

Nanamiya, Hideaki ^{[2
]}

Imai, Jun-ichi ^{[2
]}

Isogai, Takao ^{[2
]}

Watanabe, Shinya ^{[2
]}

Suzuki, Hiroyuki ^{[1
]}

机构：

[1] Fukushima Med Univ, Dept Chest Surg, Fukushima, Japan

[2] Fukushima Med Univ, Translat Res Ctr, Fukushima, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 08期

基金：

日本学术振兴会;

关键词：

Tumor mutation burden; NSCLC; Prognosis; Immune-checkpoint inhibitor; NIVOLUMAB;

D O I：

10.1016/j.jtho.2018.04.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction: Tumor mutation burden (TMB) is thought to be associated with the amount of neoantigen in the tumor and to have an important role in predicting the effect of immune checkpoint inhibitors. However, the relevance of TMB to prognosis is not yet fully understood. In this study, we investigated the clinical significance of TMB in patients with NSCLC and examined the relationship between TMB and prognosis. Methods: We calculated TMB within individual tumors by whole-exome sequencing analysis using next-generation sequencing. We included that there were 90 patients with NSCLC who underwent surgery in the Hospital of Fukushima Medical University from 2013 to 2016. No patients received chemotherapy or immunotherapy before surgery. We assessed the correlation between TMB and prognosis. Results: TMB greater than 62 was associated with worse overall survival (OS) of patients with NSCLC (hazard ratio [HR] = 6.633, p = 0.0003). Multivariate analysis showed poor prognosis with high TMB (HR = 12.31, p = 0.019). In patients with stage I NSCLC, higher TMB was associated with worse prognosis for both OS (HR = 7.582, p = 0.0018) and disease-free survival (HR = 6.07, p = 0.0072). Conclusions: High TMB in NSCLC is a poor prognostic factor. If high TMB is a predictor of the efficacy of immune checkpoint inhibitors, postoperative adjuvant therapy with immune checkpoint inhibitors may contribute to improvement of recurrence and OS. (C) 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

引用

页码：1217 / 1221

页数：5

共 8 条

[1] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[2] Comprehensive molecular profiling of lung adenocarcinoma [J].

Collisson, Eric A. ;

Campbell, Joshua D. ;

Brooks, Angela N. ;

Berger, Alice H. ;

Lee, William ;

Chmielecki, Juliann ;

Beer, David G. ;

Cope, Leslie ;

Creighton, Chad J. ;

Danilova, Ludmila ;

Ding, Li ;

Getz, Gad ;

Hammerman, Peter S. ;

Hayes, D. Neil ;

Hernandez, Bryan ;

Herman, James G. ;

Heymach, John V. ;

Jurisica, Igor ;

Kucherlapati, Raju ;

Kwiatkowski, David ;

Ladanyi, Marc ;

Robertson, Gordon ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Sinha, Rileen ;

Sougnez, Carrie ;

Tsao, Ming-Sound ;

Travis, William D. ;

Weinstein, John N. ;

Wigle, Dennis A. ;

Wilkerson, Matthew D. ;

Chu, Andy ;

Cherniack, Andrew D. ;

Hadjipanayis, Angela ;

Rosenberg, Mara ;

Weisenberger, Daniel J. ;

Laird, Peter W. ;

Radenbaugh, Amie ;

Ma, Singer ;

Stuart, Joshua M. ;

Byers, Lauren Averett ;

Baylin, Stephen B. ;

Govindan, Ramaswamy ;

Meyerson, Matthew ;

Rosenberg, Mara ;

Gabriel, Stacey B. ;

Cibulskis, Kristian ;

Sougnez, Carrie ;

Kim, Jaegil ;

Stewart, Chip .

NATURE, 2014, 511 (7511) :543-550

[3] Comprehensive genomic characterization of squamous cell lung cancers [J].

Hammerman, Peter S. ;

Lawrence, Michael S. ;

Voet, Douglas ;

Jing, Rui ;

Cibulskis, Kristian ;

Sivachenko, Andrey ;

Stojanov, Petar ;

McKenna, Aaron ;

Lander, Eric S. ;

Gabriel, Stacey ;

Getz, Gad ;

Sougnez, Carrie ;

Imielinski, Marcin ;

Helman, Elena ;

Hernandez, Bryan ;

Pho, Nam H. ;

Meyerson, Matthew ;

Chu, Andy ;

Chun, Hye-Jung E. ;

Mungall, Andrew J. ;

Pleasance, Erin ;

Robertson, A. Gordon ;

Sipahimalani, Payal ;

Stoll, Dominik ;

Balasundaram, Miruna ;

Birol, Inanc ;

Butterfield, Yaron S. N. ;

Chuah, Eric ;

Coope, Robin J. N. ;

Corbett, Richard ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Anhe Carrie ;

Hirst, Martin ;

Holt, Robert A. ;

Lee, Darlene ;

Li, Haiyan I. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Karen ;

Nip, Ka Ming ;

Olshen, Adam ;

Schein, Jacqueline E. ;

Slobodan, Jared R. ;

Tam, Angela ;

Thiessen, Nina ;

Varhol, Richard ;

Zeng, Thomas ;

Zhao, Yongjun ;

Jones, Steven J. M. .

NATURE, 2012, 489 (7417) :519-525

[4]

Hellmann MD, 2017, LANCET ONCOL, V18, P31, DOI [10.1016/s1470-2045(16)30624-6, 10.1016/S1470-2045(16)30624-6]

[5]

Horn L, 2017, J CLIN ONCOL

[6] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer [J].

Reck, Martin ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Leiby, Melanie A. ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Rangwala, Reshma ;

Brahmer, Julie R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1823-1833

[7] Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer [J].

Rizvi, Naiyer A. ;

Hellmann, Matthew D. ;

Snyder, Alexandra ;

Kvistborg, Pia ;

Makarov, Vladimir ;

Havel, Jonathan J. ;

Lee, William ;

Yuan, Jianda ;

Wong, Phillip ;

Ho, Teresa S. ;

Miller, Martin L. ;

Rekhtman, Natasha ;

Moreira, Andre L. ;

Ibrahim, Fawzia ;

Bruggeman, Cameron ;

Gasmi, Billel ;

Zappasodi, Roberta ;

Maeda, Yuka ;

Sander, Chris ;

Garon, Edward B. ;

Merghoub, Taha ;

Wolchok, Jedd D. ;

Schumacher, Ton N. ;

Chan, Timothy A. .

SCIENCE, 2015, 348 (6230) :124-128

[8] Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set [J].

Roszik, Jason ;

Haydu, Lauren E. ;

Hess, Kenneth R. ;

Oba, Junna ;

Joon, Aron Y. ;

Siroy, Alan E. ;

Karpinets, Tatiana V. ;

Stingo, Francesco C. ;

Baladandayuthapani, Veera ;

Tetzlaff, Michael T. ;

Wargo, Jennifer A. ;

Chen, Ken ;

Forget, Marie-Andree ;

Haymaker, Cara L. ;

Chen, Jie Qing ;

Meric-Bernstam, Funda ;

Eterovic, Agda K. ;

Shaw, Kenna R. ;

Mills, Gordon B. ;

Gershenwald, Jeffrey E. ;

Radvanyi, Laszlo G. ;

Hwu, Patrick ;

Futreal, P. Andrew ;

Gibbons, Don L. ;

Lazar, Alexander J. ;

Bernatchez, Chantale ;

Davies, Michael A. ;

Woodman, Scott E. .

BMC MEDICINE, 2016, 14

← 1 →